Ken Griffin Monte Rosa Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$3.38 - $7.86 $12,168 - $28,296	-3,600 Reduced 23.53%	11,700 $43,000
Q1 2024 May 15, 2024	SELL	$4.26 - $8.46 $121,410 - $241,110	-28,500 Reduced 65.07%	15,300 $107,000
Q4 2023 Feb 14, 2024	BUY	$2.5 - $5.93 $92,500 - $219,410	37,000 Added 544.12%	43,800 $247,000
Q3 2023 Nov 14, 2023	SELL	$4.78 - $7.22 $168,256 - $254,144	-35,200 Reduced 83.81%	6,800 $32,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $8.4 $4,077 - $7,560	-900 Reduced 2.1%	42,000 $287,000
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $144,585 - $199,503	24,300 Added 130.65%	42,900 $334,000
Q4 2022 Feb 14, 2023	BUY	$6.71 - $9.72 $124,806 - $180,792	18,600 New	18,600 $141,000

40.6M

84.2K

20.6K

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $303M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.